HK Stock Movement | IMMUNEONCO-B (01541) Surges Over 9% in Afternoon Trading as IMM0306 Phase III Clinical Trial Plan Approved by CDE

Stock News11-27

IMMUNEONCO-B (01541) rose more than 9% in afternoon trading, reaching a 7.98% gain at press time to HK$7.31, with a turnover of HK$10.70 million. The company announced during the midday break that its Phase III clinical trial plan for IMM0306 combined with lenalidomide in treating relapsed/refractory follicular lymphoma has been approved by the Center for Drug Evaluation (CDE). This marks an acceleration in the development of innovative therapies for relapsed/refractory follicular lymphoma.

IMM0306 is the world's first CD47 and CD20 dual-targeting bispecific molecule to enter clinical trials. It blocks the "don't eat me" signal, activates macrophages and NK cells, and preferentially binds to CD20 over CD47, effectively eliminating malignant B cells while minimizing toxicity to enhance therapeutic outcomes. The company holds global intellectual property and commercialization rights for IMM0306.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1157057375?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 13:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157057375","market":"sg","top_or_hot":-1,"title":"HK Stock Movement | IMMUNEONCO-B (01541) Surges Over 9% in Afternoon Trading as IMM0306 Phase III Clinical Trial Plan Approved by CDE","media":"Stock News","content":"<p>IMMUNEONCO-B (01541) rose more than 9% in afternoon trading, reaching a 7.98% gain at press time to HK$7.31, with a turnover of HK$10.70 million. The company announced during the midday break that its Phase III clinical trial plan for IMM0306 combined with lenalidomide in treating relapsed/refractory follicular lymphoma has been approved by the Center for Drug Evaluation (CDE). This marks an acceleration in the development of innovative therapies for relapsed/refractory follicular lymphoma.</p>\n<p>IMM0306 is the world's first CD47 and CD20 dual-targeting bispecific molecule to enter clinical trials. It blocks the \"don't eat me\" signal, activates macrophages and NK cells, and preferentially binds to CD20 over CD47, effectively eliminating malignant B cells while minimizing toxicity to enhance therapeutic outcomes. The company holds global intellectual property and commercialization rights for IMM0306.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | IMMUNEONCO-B (01541) Surges Over 9% in Afternoon Trading as IMM0306 Phase III Clinical Trial Plan Approved by CDE</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | IMMUNEONCO-B (01541) Surges Over 9% in Afternoon Trading as IMM0306 Phase III Clinical Trial Plan Approved by CDE\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-27 13:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>IMMUNEONCO-B (01541) rose more than 9% in afternoon trading, reaching a 7.98% gain at press time to HK$7.31, with a turnover of HK$10.70 million. The company announced during the midday break that its Phase III clinical trial plan for IMM0306 combined with lenalidomide in treating relapsed/refractory follicular lymphoma has been approved by the Center for Drug Evaluation (CDE). This marks an acceleration in the development of innovative therapies for relapsed/refractory follicular lymphoma.</p>\n<p>IMM0306 is the world's first CD47 and CD20 dual-targeting bispecific molecule to enter clinical trials. It blocks the \"don't eat me\" signal, activates macrophages and NK cells, and preferentially binds to CD20 over CD47, effectively eliminating malignant B cells while minimizing toxicity to enhance therapeutic outcomes. The company holds global intellectual property and commercialization rights for IMM0306.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1157057375","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157057375","pubTimestamp":1764222974,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"IMMUNEONCO-B (01541) rose more than 9% in afternoon trading, reaching a 7.98% gain at press time to HK$7.31, with a turnover of HK$10.70 million. The company announced during the midday break that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B","BK4017":"黄金","BK1161":"生物科技","CDE":"科尔黛伦矿业","BK4134":"信息科技咨询与其它服务","LU1223083913.SGD":"Schroder ISF Global Gold A Acc SGD-H","LU1223082519.USD":"SCHRODER ISF GLOBAL GOLD \"A\" (USD) INC AV","III":"信息服务","LU1223082196.USD":"施罗德环球黄金A Acc"},"translate_title":"港股动向|IMM0306 III期临床试验方案获CDE批准IMMUNEONCO-B(01541)午盘大涨超9%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1,"CDE":1,"01541":1},"content_text":"IMMUNEONCO-B (01541) rose more than 9% in afternoon trading, reaching a 7.98% gain at press time to HK$7.31, with a turnover of HK$10.70 million. The company announced during the midday break that its Phase III clinical trial plan for IMM0306 combined with lenalidomide in treating relapsed/refractory follicular lymphoma has been approved by the Center for Drug Evaluation (CDE). This marks an acceleration in the development of innovative therapies for relapsed/refractory follicular lymphoma.\nIMM0306 is the world's first CD47 and CD20 dual-targeting bispecific molecule to enter clinical trials. It blocks the \"don't eat me\" signal, activates macrophages and NK cells, and preferentially binds to CD20 over CD47, effectively eliminating malignant B cells while minimizing toxicity to enhance therapeutic outcomes. The company holds global intellectual property and commercialization rights for IMM0306.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1157057375","isCrawlerRequest":true}